The Neurodegeneration Revolution

Emerging Therapies and Sustainable Solutions

1st Edition - November 19, 2024
Editors: Trideva Sastri Koduru, Riyaz Ali M Osmani, Ekta Singh, Suman Dutta
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 2 8 8 2 2 - 7
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 8 8 2 3 - 4

The Neurodegeneration Revolution: Emerging Therapies and Sustainable Solutions provides insights into the mechanics, characteristics, behavior, application, and manufa… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

The Neurodegeneration Revolution: Emerging Therapies and Sustainable Solutions provides insights into the mechanics, characteristics, behavior, application, and manufacturing of advanced materials such as nanowires, 2D materials, biomaterials, smart materials, and more. The first section discusses the mechanics and electronic and magnetic properties of nanomaterials, photonic, and photonic materials and devices, 2D magnetic materials, smart materials and coatings, metamaterials, and microdevices and sensors. The second section of the book covers manufacturing technologies and methods of previously discussed materials, outlining manufacturing techniques for additive manufacturing of metallic lattice structures, biomedical alloys, shape memory alloys, multifunctional polymer composites, nanocomposite structures, ceramics, and batteries.

The Neurodegeneration Revolution
Cover image
Title page
Table of Contents
Copyright
Contributors
About the editors
Foreword
Preface
Acknowledgments
Section 1: Neurodegeneration and basics
Chapter 1 An introduction to neurodegenerative disorders: Pathophysiology, hallmarks, and mechanisms at a glance
Abstract
Keywords
1.1 Introduction
1.2 Types of neurodegenerative diseases
1.2.1 Polyglutamine diseases
1.2.2 Alzheimer's disease
1.2.3 Huntington's disease
1.2.4 Parkinson's disease
1.2.5 Amyotrophic lateral sclerosis
1.2.6 Prion diseases
1.3 Hallmarks of neurodegenerative diseases
1.3.1 Protein aggregation
1.3.2 Neuronal dysfunctions
1.3.3 Atypical proteostasis
1.3.4 Cytoskeletal deformities
1.3.5 Different energy homeostasis
1.3.6 Nucleic acid defects
1.3.7 Inflammation
1.3.8 Neuronal cell death
1.4 NDDs at glance
1.5 Models, mechanisms, and more at a glance
1.6 Conclusion and future perspectives
References
Chapter 2 Molecular etiopathogenesis of neurodegenerative diseases
Abstract
Keywords
2.1 Introduction
2.2 Alzheimer's disease
2.2.1 Protein misfolding and aggregation
2.2.2 Genetic factors
2.2.3 Oxidative stress
2.2.4 Inflammatory processes
2.2.5 Mitochondrial dysfunction
2.2.6 Excitotoxicity
2.2.7 Epigenetic modifications
2.3 Parkinson's disease
2.3.1 Protein aggregation and misfolding
2.3.2 Genetic factors
2.3.3 Oxidative stress
2.3.4 Inflammatory processes
2.3.5 Mitochondrial dysfunction
2.3.6 Excitotoxicity
2.3.7 Epigenetic modifications
2.4 Amyotrophic lateral sclerosis
2.4.1 Protein misfolding and aggregation
2.4.2 Genetic factors
2.4.3 Oxidative stress
2.4.4 Inflammatory processes
2.4.5 Mitochondrial dysfunction
2.4.6 Excitotoxicity
2.4.7 Epigenetic modifications
References
Chapter 3 The genetic face of brain diseases
Abstract
Keywords
References
Chapter 4 Diagnosis and management of neurodegenerative diseases
Abstract
Keywords
4.1 Introduction
4.2 Alzheimer's disease
4.2.1 Overview of Alzheimer's disease
4.2.2 Epidemiology
4.2.3 Diagnosis
4.2.4 Management
4.3 Parkinson's disease
4.3.1 Diagnosis
4.3.2 Management
4.4 Huntington's disease
4.4.1 Diagnosis
4.4.2 Management
4.5 Conclusion
References
Section 2: Established therapies for managing neurodegeneration
Chapter 5 Current pharmacological treatments for neurodegenerative diseases
Abstract
Keywords
5.1 Introduction
5.2 Current pharmacological treatments for neurodegenerative diseases
5.2.1 Cholinesterase inhibitors
5.2.2 NMDA receptor antagonists
5.2.3 Dopamine replacement therapy
5.3 Challenges and future directions
5.3.1 Limitations of current pharmacological treatments
5.3.2 Emerging therapies and research frontiers
5.4 Conclusion
References
Chapter 6 Nonpharmacological therapies for neurodegenerative disorders
Abstract
Keywords
6.1 Introduction
6.1.1 Definition of neurodegenerative diseases
6.1.2 Prevalence and impact of NDDs
6.1.3 Importance of nonpharmacological interventions
6.2 Nonpharmacological therapies
6.2.1 Physical therapy
6.2.2 Cognitive training, stimulation, and rehabilitation
6.2.3 Psychotherapy
6.2.4 Lifestyle modification
6.2.5 Electroconvulsive therapy
6.2.6 Noninvasive brain stimulation
6.2.7 Assistive technologies
6.2.8 Acupuncture
6.2.9 Others
6.3 Mechanisms and benefits
6.3.1 Role of neuroplasticity
6.3.2 Improvement in quality of life, functional enhancement, delayed progression
6.4 Challenges and future directions
6.4.1 Cost and affordability
6.4.2 Personalization of therapy
6.4.3 Role of emerging technologies
6.5 Conclusion
6.5.1 Recap of the importance of non-pharmacological therapies
6.5.2 Call to action for holistic care approaches
References
Chapter 7 The role of nutrition in neurodegeneration
Abstract
Keywords
7.1 Introduction to neurodegeneration
7.2 Importance of nutritional interventions in neurodegeneration
7.3 Mechanisms of neurodegeneration
7.3.1 Oxidative stress
7.3.2 Inflammation
7.3.3 Protein aggregation
7.4 Role of nutritional deficiencies in neurodegeneration
7.4.1 Micronutrient deficiencies
7.4.2 Omega-3 fatty acid deficiency
7.4.3 Antioxidants deficiency
7.5 Nutritional factors in neuroprotection
7.5.1 Antioxidants
7.5.2 Selenium
7.5.3 Polyphenols
7.5.4 Omega-3 fatty acids: DHA and EPA
7.6 Dietary patterns and neurodegenerative diseases
7.6.1 Alzheimer's disease
7.6.2 Parkinson's disease
7.6.3 Huntington's disease
7.6.4 Amyotrophic lateral sclerosis
7.6.5 Link between gut-brain axis and neurodegeneration
7.7 Clinical evidence and research findings
7.8 Practical recommendations
7.8.1 Dietary guidelines for neuroprotection
7.8.2 Supplement recommendations
7.9 Challenges and considerations
7.10 Future directions and research needs
7.10.1 Patient education and empowerment
7.10.2 Empowering patients to make informed choices
7.10.3 Resources for patients and caregivers
7.10.4 Collaboration with healthcare professionals
7.10.5 Technological solutions and digital health
7.10.6 Public health implications
7.10.7 Global perspectives on nutritional interventions
References
Chapter 8 The impact of microbiological infections on neurodegenerative diseases
Abstract
Keywords
8.1 Introduction
8.2 Microbes and neurodegenerative diseases
8.3 ADs and microbial pathogens
8.4 HD and pathogens
8.5 PD and pathogens
8.6 Amyotrophic lateral sclerosis and microbes
8.7 Conclusion and future perspectives
References
Section 3: Advanced therapies and novel—New age delivery systems
Chapter 9 Gene therapy for neurodegenration
Abstract
Keywords
9.1 Introduction
9.2 Principles of gene therapy
9.3 Types of gene therapy approaches
9.3.1 Gene augmentation
9.3.2 Gene silencing
9.3.3 Genome editing
9.4 Gene delivery strategies for neurodegenerative disorders
9.4.1 Viral vectors
9.4.2 Nonviral vectors and their applications
9.4.3 Challenges and considerations in CNS-specific gene delivery
9.5 Gene therapy approaches for specific neurodegenerative disorders
9.5.1 Alzheimer's disease genetic targets
9.5.2 Amyloid precursor protein
9.5.3 Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2)
9.5.4 Apolipoprotein E (APOE)
9.5.5 SORL1 (sortilin-related receptor)
9.5.6 PD genetic targets
9.5.7 Alpha-synuclein (SNCA)
9.5.8 Leucine-rich repeat kinase 2 (LRRK2)
9.5.9 Parkin (PRKN)
9.5.10 PTEN-induced kinase 1 (PINK1)
9.5.11 Glucocerebrosidase
9.5.12 Huntington's disease
9.5.13 HTT gene
9.5.14 CAG repeat expansion
9.6 Case study: Clinical trials in SMA treatment
9.7 Regulatory challenges
9.8 Gene editing technologies in neurodegenerative disorders
9.9 Future directions
References
Chapter 10 Stem cell-based therapy for neurodegenerative disorders: progress and challenges
Abstract
Keywords
Acknowledgments
10.1 Introduction
10.2 Stem cells as a novel therapy for neurodegenerative disorders
10.2.1 Embryonic stem cells
10.2.2 Induced pluripotent stem cells
10.2.3 Mesenchymal stem cells
10.2.4 Neural stem cells
10.3 Mechanisms of action of stem cells in neurodegenerative disorder treatment
10.3.1 Neuronal replacement and regeneration
10.3.2 Integration of transplanted neurons into the existing neural circuitry
10.3.3 Neurotrophic support and growth factor secretion
10.3.4 Anti-inflammatory and immunomodulatory effects
10.4 Preclinical studies of SCT for neurodegenerative disorders
10.5 Overview of ongoing and completed clinical trials
10.6 Challenges and considerations
10.6.1 Immune rejection and immune response modulation
10.6.2 Optimization of stem cell delivery methods
10.6.3 Long-term effects and monitoring of transplanted cells
10.6.4 Ethical considerations and regulatory challenges
10.7 Regulatory frameworks and guidelines for stem cell-based therapies
10.8 Future directions and potential applications
10.8.1 Advances in stem cell technology and genetic engineering
10.8.2 Combination therapies and personalized medicine approaches
10.8.3 Potential for disease modification and slowing disease progression
10.9 Conclusions
References
Chapter 11 Nanoparticle-mediated drug delivery for neurodegenerative diseases
Abstract
Keywords
11.1 Introduction
11.2 Neurogenerative diseases
11.2.1 Alzheimer's disease
11.2.2 Parkinson's disease
11.2.3 Huntington's disease
11.2.4 Multiple sclerosis
11.2.5 Amyotrophic lateral sclerosis
11.3 Approaches and mechanisms of drug delivery to the brain
11.3.1 Invasive techniques
11.3.2 Noninvasive methods
11.4 Nanoparticle-mediated drug delivery for NDDs management
11.4.1 Polymeric nanoparticles
11.4.2 Lipid-based nanoparticles
11.4.3 Metal-based nanoparticles
11.4.4 Carbon-based nanoparticles
11.5 Conclusions
References
Chapter 12 Exosomes and extracellular vesicles for neurodegenerative diseases
Abstract
Keywords
12.1 Introduction
12.2 Cellular communication and EV types
12.3 Biogenesis of exosomes
12.4 Functions of brain-originating EVs
12.5 Involvement of EVs in the CNS microenvironment during neurodegeneration
12.6 Contribution of EVs to neurodegenerative disease progression and pathology
12.7 Emerging evidence from research studies and clinical trials
12.8 Isolation, characterization, and analysis of CNS-originating EVs
12.9 Techniques for isolation and purification of total EVs
12.10 EV characterization
12.11 EV biomarkers in neurodegenerative diseases
12.11.1 AD
12.11.2 PD
12.11.3 MSA
12.11.4 ALS
12.11.5 HD
12.12 Therapeutic potential of EVs in neurodegenerative diseases
12.13 Delivery mechanisms and targeting strategies
12.14 Preclinical and clinical studies exploring the therapeutic efficacy of EVs
12.15 Challenges and future directions
References
Section 4: Sustainable green nanotechnology and integration of AI/ML for developing nano carriers
Chapter 13 Harnessing sustainable green nanotechnology: Recent advancements in neurodegenerative disease therapeutics
Abstract
Keywords
Acknowledgments
13.1 Introduction
13.2 Neurological drug delivery: Advances in crossing the BBB
13.3 Green nanosystems revolutionizing NDD management: Exploring green neuro-nanotechnology
13.4 Advances in phyto-neuro medicine
13.4.1 Protein-based nanoparticles
13.4.2 Polymeric nanoparticles (PNPs)
13.4.3 Liposomes-based DDS
13.4.4 Green synthesized nanomaterials
13.5 Challenges and future prospects
13.6 Conclusions
References
Chapter 14 AI/ML-driven nanocarriers for the management of neurodegeneration
Abstract
Keywords
14.1 Introduction
14.2 Understanding neurogenerative disorders and need for nanocarriers
14.3 Nanocarriers: Basics and applications
14.4 Role of predictive algorithms in nanocarrier design
14.4.1 Overview of predictive algorithms in AI/ML
14.4.2 Application of predictive algorithms in drug delivery systems
14.4.3 Examples of predictive algorithms used in nanocarrier design for neurogenerative disorders
14.5 Overview of predictive algorithms in AI/ML for the optimization of nanocarriers
14.5.1 Importance of AI/ML in advancing nanocarrier development for neurogenerative disorder treatment
14.6 Current challenges in AI/ML-based nanocarrier development include [34]
14.7 Ethical considerations and regulatory aspects
14.8 Potential future directions and advancements in AI/ML
References
Chapter 15 Synergizing sustainable green nanotechnology and AI/ML for advanced nanocarriers: A paradigm shift in the treatment of neurodegenerative diseases
Abstract
Keywords
15.1 Introduction
15.1.1 Background and rationale
15.1.2 Objectives of the chapter
15.1.3 Significance of sustainable nanotechnology and AI/ML integration
15.2 Foundations of sustainable green nanotechnology
15.2.1 Sustainable principles of nanotechnology
15.2.2 Eco-friendly nanomaterials
15.2.3 Environmental impact and considerations
15.3 AI/ML in nanocarrier development
15.3.1 Role of AI/ML in nanotechnology
15.3.2 Intelligent design and computational approaches
15.3.3 Predictive modeling for nanocarrier optimization
15.4 Convergence of sustainable nanotechnology and AI/ML
15.4.1 Synergistic applications in nanocarrier development
15.5 Benefits and innovations in nanocarrier design
15.5.1 Enhanced drug delivery efficiency
15.5.2 Precision medicine applications
15.5.3 Therapeutic advancements in neurodegenerative diseases
15.6 Challenges and ethical considerations
15.6.1 Ethical implications of AI/ML in healthcare
15.6.2 Responsible innovation in nanomedicine
15.6.3 Regulatory perspectives
15.7 Future directions and opportunities
15.7.1 Emerging trends in sustainable nanotechnology
15.7.2 Advancements in AI/ML technologies
15.7.3 Unexplored avenues in neurodegenerative disease research
15.8 Conclusion
References
Chapter 16 Navigating the nanoscopic frontier: Ethical dimensions in developing nanocarriers for neurodegenerative diseases
Abstract
Keywords
Conflict of interest
16.1 Introduction
16.1.1 Background
16.1.2 Significance of nanocarriers in neurodegenerative disease treatment
16.1.3 The ability of medicinal nanocarriers to last a long time in the blood
16.1.4 Types of nanocarriers
16.2 Nanocarriers: A primer
16.2.1 Synopsis of technologies using liposome-derived nanocarriers
16.2.2 Applications of nanocarriers in neurodegenerative disease therapy
16.3 Ethical considerations in nanocarrier development
16.3.1 Safety and toxicity assessment
16.3.2 Risk assessment of nanocarriers
16.4 Regulatory requirements
16.4.1 USA
16.4.2 Japan
16.4.3 Canada
16.4.4 India
16.5 Drug loading in nanocarriers and release strategy
16.5.1 Covalent bonding
16.5.2 Encapsulation
16.5.3 Electrostatic interactions
16.6 Future prospectives
16.7 Conclusion
References
Section 5: Emerging frontiers in neurodegenerative disease management
Chapter 17 Recent progress in biomarkers for neurodegenerative disorders
Abstract
Keywords
17.1 Introduction
17.2 Salivary biomarkers for neurodegenerative disease
17.2.1 Potential of salivary biomarkers for early diagnosis and monitoring
17.3 CSF biomarkers in AD
17.4 Redox homeostasis and therapeutic targeting in neurodegenerative disease
17.4.1 Role of redox homeostasis in neurodegenerative disorders and prospects for therapeutic targeting
17.4.2 Advancements in genetics and mechanisms of neuronal pathogenesis and their implications for innovative technologies and therapeutic interventions against neurodegenerative diseases
17.5 Exosomes as diagnostic and therapeutic tools in AD
17.5.1 Diagnostic and therapeutic potential of exosomes in AD
17.5.2 Use of exosomes as a source of biomarkers and their potential in unraveling disease mechanisms
17.6 Salivary redox biomarkers in neurodegenerative disease
17.6.1 Investigation of salivary redox biomarkers in selected neurodegenerative diseases
17.7 Emerging discoveries biomarkers for neurological disorders
17.7.1 Revolutionizing AD and clinical trials through biomarkers
17.7.2 Applications of proteomics in neurodegenerative
17.8 Challenge and future direction in neurodegenerative biomarker research
17.9 Conclusions
References
Chapter 18 Ethical dimensions in neurodegenerative disease management: A comprehensive analysis
Abstract
Keywords
18.1 Introduction
18.2 Autonomy
18.3 Informed consent
18.4 Access to care
18.4.1 Affordability
18.4.2 Availability
18.4.3 Accessibility
18.4.4 Accommodation
18.4.5 Acceptability
18.5 End-of-life
18.6 Significance of ethical and social issues
18.7 Patient-centric care
18.7.1 Empowered decision-making
18.7.2 Guidance for healthcare professionals
18.8 Conclusions
References
Chapter 19 Resilience in caregiving in neurodegenerative disease complexities
Abstract
Keywords
19.1 Introduction
19.2 Caregivers
19.3 Daily responsibilities of caregiving
19.4 Understanding the impact on caregivers
19.5 Emotional and psychological challenges faced by caregivers
19.6 Building a supportive caregiver network
19.7 Coping strategies for caregiver burnout [41]
19.8 Communication skills in caregiving
19.8.1 Nonverbal communication
19.8.2 Empathy
19.8.3 Adaptive interaction
19.8.4 Clarity and simplification
19.8.5 Embracing validation and validation therapy
19.8.6 Emerging technology for communication
19.9 Balancing self-care and caregiving responsibilities
19.9.1 Signs and symptoms of caregiver stress and burnout
19.9.2 Risk factors of caregiver stress and burden
19.10 Strategies to balance self-care and caregiving responsibilities
19.11 Future trends in caregiving for neurodegenerative diseases
19.12 Conclusion: Recognizing and honoring the role of caregivers in neurodegenerative diseases
References
Chapter 20 Exploring the neurodegenerative landscape: Understanding the burden of disease
Abstract
Keywords
20.1 Introduction
20.2 Distinct categories of neurodegenerative disease (acute and chronic)
20.2.1 Acute neurodegenerative diseases
20.2.2 Chronic neurodegenerative diseases
20.3 Several types of neurodegenerative diseases
20.3.1 Alzheimer's disease (AD)
20.3.2 Parkinson's disease (PD)
20.3.3 Huntington's disease (HD)
20.3.4 Amyotrophic lateral sclerosis (ALS)
20.3.5 Frontotemporal dementia (FTD)
20.3.6 Prion diseases (e.g., Creutzfeldt-Jakob disease)
20.4 Methodology
20.4.1 Operational definitions [1,5]
20.5 Global burden of neurological disease
20.6 Indian burden of neurological disease
20.6.1 Statewise data
20.7 Discussion
20.8 Integrated care models for neurological diseases
20.9 Out-of-pocket expenditure and government-based schemes for neurodegenerative disease
20.10 Access to healthcare for neurodegenerative diseases
20.11 Limitations
20.12 Conclusions
References
Section 6: Clinical trials and recent research, future directions, and conclusion
Chapter 21 Clinical trials for neurodegenerative diseases
Abstract
Keywords
21.1 Introduction
21.2 Challenges in conducting clinical trials for neurodegenerative disorders
21.3 Ethical considerations: Patient's safety and issues
21.4 Recent developments in clinical trial methodology and technology
21.5 Landmark trials in neurocognitive disorders
21.5.1 Alzheimer's disease (AD)
21.5.2 Amyotrophic lateral sclerosis (ALS)
21.5.3 Parkinson's disease
21.5.4 Huntington's disease
21.6 Research and development in neurodegenerative disorders could explore several promising areas
21.7 Conclusion
21.8 Effects on patient care
21.9 Recommendations
References
Chapter 22 Recent advances in neurodegenerative disease research
Abstract
Keywords
22.1 Introduction
22.2 Contemporary hallmarks of neurodegenerative diseases
22.2.1 Neuronal damage
22.2.2 Prions, protein misfolding, and aggregation
22.2.3 Genetic and nucleic acid defects
22.2.4 Mechanobiological or cytoskeletal aberrations
22.2.5 Metabolic and mitochondrial dysfunction
22.2.6 Immune dysfunction
22.3 Recent advances in prevention of neurodegenerative disorders
22.3.1 Cell-autonomous neurodegeneration
22.3.2 Noncell-autonomous neurodegeneration
22.4 Challenges in this domain
22.5 Summary and conclusions
References
Chapter 23 Future directions for neurodegenerative disease management
Abstract
Keywords
23.1 Introduction
23.2 Precision medicine paradigm
23.3 Immunotherapy
23.4 Innovative gene therapy
23.5 Neurodegeneration
23.6 Neuroinflammation
23.7 Wearable technology and digital health
23.8 Lifestyle interventions
23.9 Artificial intelligence_ The way forward?
23.10 Interdisciplinary collaborations for holistic care
23.11 Conclusion
References
Chapter 24 Challenges and opportunities in neurodegenerative diseases management
Abstract
Keywords
24.1 Introduction
24.2 Diagnostic dilemmas
24.2.1 Early detection failure
24.2.2 Misclassification bias
24.2.3 Variability of disease symptoms
24.2.4 Challenges with diagnostic techniques
24.2.5 Challenges in primary care
24.2.6 Problems in biomarkers
24.2.7 Challenges for gene sequencing method
24.2.8 Challenges with informed consent
24.3 Therapeutic challenges
24.3.1 Drug delivery approaches
24.3.2 Drug repurposing
24.3.3 Nature of drug carriers
24.4 Intervention types
24.4.1 Stem-cell based therapy
24.4.2 Gene therapy
24.4.3 Natural products-based intervention
24.4.4 Resource limitations
24.4.5 Emerging technologies: A beacon of hope
24.4.6 Policy implications in neurodegenerative diseases management
24.4.7 Diagnosis of neurodegenerative diseases
24.4.8 Innovative treatment approaches
24.4.9 Neuroprotective agents and antioxidants
24.4.10 Multidisciplinary care models
24.4.11 Economic and social support
24.4.12 Health promotion
24.4.13 Collaborative approaches in neurodegenerative diseases management
24.4.14 Neurologists and primary care physicians
24.4.15 Nurses
24.4.16 Physical and occupational therapists
24.4.17 Pharmacists
24.4.18 Psychologists and social workers
24.4.19 Caregivers
24.4.20 Case management and coordinators
24.4.21 Technological integration
24.4.22 Patients
24.4.23 Potential for personalized medicine
24.4.24 Ethical considerations in neurodegenerative care
24.5 Conclusion
References
Index

Trideva Sastri Koduru

Dr. Trideva Sastri Koduru, Ph.D., currently holds a faculty position in the Department of Pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research in Mysuru, Karnataka, India. His doctoral research was a pioneering exploration into miRNA-based therapies for managing Multiple Sclerosis, garnering recognition through a Senior Research Fellowship from the Innovation and Translation Research division of the Indian Council of Medical Research (ICMR), New Delhi, India. His work published in journals of international repute, including Drug Discovery Today, Dr. Sastri's research explores into nanoscience-aided drug carrier systems and the genetic intricacies of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. Dr. Sastri envisions a future characterized by continued research in drug delivery systems. His forthcoming endeavors center on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences.

Affiliations and expertise

Dept of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.

Riyaz Ali M Osmani

Dr. Riyaz Ali M Osmani, Ph.D., completed his graduation and post-graduation in Pharmacy from Shivaji University, Kolhapur, followed by his Doctoral Research from JSS Academy of Higher Education and Research (JSS AHER), Mysuru. He continued his Postdoctoral Research at Department of Biosciences and Bioengineering (BSBE), Indian Institute of Technology Bombay (IITB), Mumbai, India, and later also served as a Project Research Scientist at the same Department. Till date, to his credit he has more than 157 research publications in numerous National and International journals of repute (with cumulative IF>350), and has authored many book chapters as well as review articles. Moreover, he is the reviewer of many esteemed, peer-reviewed journals. He has been conferred with various awards and honors for his scientific contributions and services. He is an active member of Indian Pharmaceutical Association (IPA), and life member of Indian Pharmaceutical Graduate Association (IPGA) and Association of Pharmaceutical Teachers of India (APTI). Furthermore, he has many achievements and recognitions at every level of curriculum. He is currently working as an Assistant Professor at the Department of Pharmaceutics, JSS College of Pharmacy, JSS AHER, Mysuru. His research interests include pharmaceutics, pharmaceutical nanotechnology, nanomedicine, pre-formulation profiling, solid state characterization, nanomaterials, microneedles technology, polymer grafting etc., to name a few. Despite nanotechnology and nanomedicines being vast research meadows; he takes special interest in developing nanocarriers based novel drug delivery systems for a range of ailments.

Affiliations and expertise

Dept of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.

Ekta Singh

Dr. Ekta Singh, Ph.D., pursued her PhD in biomedical engineering from IIT Bombay, where her research was focused on developing trigger-responsive theranostics for Rheumatoid Arthritis and is currently placed as a postdoctoral research scientist with Prof. Michael P Sheetz at UTMB Galveston. Dr Singh’s current research is focused on paracrine factors secreted by normal human fibroblasts when treated with Low-frequency Ultrasound (LFU). What makes these molecules exciting and worth exploring is that these secretory factors have the potential to rejuvenate senescent fibroblasts—furthermore, study the long-term effects of LFU on the glucose metabolism in old high-fat diabetic mice. The study's preliminary findings indicate an improved oral glucose tolerance and insulin response after LFU treatment. Additionally, her study explores the effects of mechanical stimulation via LFU on total thickness cutaneous wound healing in old mice. Being in her early research transition phase, Dr Singh is curious to learn what novel insights her research group would unveil towards mechanotherapy. She is an aspiring academician interested in developing new teaching designs and effective mentorship. When she is not with her micropipette and books, she loves playing her Ukulele. Besides, she is very fond of travelling to countryside locations and taking photos of food.

Suman Dutta

Dr. Suman Dutta, Ph.D., is a Research Scientist at the Nuffield Department of Clinical Neurosciences, University of Oxford, UK. He began his research career studying inflammation-induced macrophage apoptosis, leading to the attainment of a Ph.D. from India. Currently, he researches the potential of brain-derived blood extracellular vesicles as biomarkers for neurodegenerative diseases, with a focus on identifying cell-specific extracellular vesicle markers. Dr. Dutta's expertise in extracellular vesicle biology was developed through previous positions at renowned institutions including the University of California Los Angeles, USA. Throughout his career, he has made significant contributions to the field of extracellular vesicles and neurodegenerative disorders. Committed to the scientific community, he actively contributes through publications, presentations, journal editing, and peer review

Affiliations and expertise

Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

The Neurodegeneration Revolution

Emerging Therapies and Sustainable Solutions

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Trideva Sastri Koduru

Riyaz Ali M Osmani

Ekta Singh

Suman Dutta